Iprox
Iprox Brand names, Iprox Analogs
Iprox Brand Names Mixture
- No information avaliable
Iprox Chemical_Formula
C18H19ClN4
Iprox RX_link
http://www.rxlist.com/cgi/generic3/clozapine.htm
Iprox fda sheet
Iprox msds (material safety sheet)
Iprox Synthesis Reference
No information avaliable
Iprox Molecular Weight
326.823 g/mol
Iprox Melting Point
183-184 oC
Iprox H2O Solubility
11.8 mg/L
Iprox State
Solid
Iprox LogP
2.502
Iprox Dosage Forms
Tablet
Iprox Indication
For the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatment for schizophrenia
Iprox Pharmacology
Clozapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Clozapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Clozapine acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Clozapine. Clozapine's antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects. Clozapine's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Clozapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.
Iprox Absorption
Rapid and almost complete
Iprox side effects and Toxicity
No information avaliable
Iprox Patient Information
PATIENT INFORMATION
� Patients who are to receive CLOZARIL should be warned about the significant risk of developing agranulocytosis. They should be informed that weekly blood tests are required for the first 6 months, if acceptable WBC counts (WBC � 3000/mm3, ANC � 1500/mm3) have been maintained during the first 6 months of continuous therapy, then WBC counts can be monitored every other week in order to monitor for the occurrence of agranulocytosis, and that CLOZARIL tablets will be made available only through a special program designed to ensure the required blood monitoring. Patients should be advised to report immediately the appearance of lethargy, weakness, fever, sore throat, malaise, mucous membrane ulceration or other possible signs of infection.
Particular attention should be paid to any flu-like complaints or other symptoms that might suggest infection.
� Patients should be informed of the significant risk of seizure during CLOZARIL treatment, and they should be advised to avoid driving and any other potentially hazardous activity while taking CLOZARIL.
� Patients should be advised of the risk of orthostatic hypotension, especially during the period of initial dose titration.
� Patients should be informed that if they stop taking CLOZARIL for more than 2 days, they should not restart their medication at the same dosage, but should contact their physician for dosing instructions.
� Patients should notify their physician if they are taking, or plan to take, any prescription or over-the-counter drugs or alcohol.
� Patients should notify their physician if they become pregnant or intend to become pregnant during therapy.
� Patients should not breast-feed an infant if they are taking CLOZARIL.
� Patients who are to receive CLOZARIL should be warned about the significant risk of developing agranulocytosis. They should be informed that weekly blood tests are required for the first 6 months, if acceptable WBC counts (WBC � 3000/mm3, ANC � 1500/mm3) have been maintained during the first 6 months of continuous therapy, then WBC counts can be monitored every other week in order to monitor for the occurrence of agranulocytosis, and that CLOZARIL tablets will be made available only through a special program designed to ensure the required blood monitoring. Patients should be advised to report immediately the appearance of lethargy, weakness, fever, sore throat, malaise, mucous membrane ulceration or other possible signs of infection.
Particular attention should be paid to any flu-like complaints or other symptoms that might suggest infection.
� Patients should be informed of the significant risk of seizure during CLOZARIL treatment, and they should be advised to avoid driving and any other potentially hazardous activity while taking CLOZARIL.
� Patients should be advised of the risk of orthostatic hypotension, especially during the period of initial dose titration.
� Patients should be informed that if they stop taking CLOZARIL for more than 2 days, they should not restart their medication at the same dosage, but should contact their physician for dosing instructions.
� Patients should notify their physician if they are taking, or plan to take, any prescription or over-the-counter drugs or alcohol.
� Patients should notify their physician if they become pregnant or intend to become pregnant during therapy.
� Patients should not breast-feed an infant if they are taking CLOZARIL.
Iprox Organisms Affected
Humans and other mammals
